On October 18th, Nicolas Giraud, global CEO of French Mayoly Spinder Group, and his party visited Tianjin Pharmaceutical Holdings Co., Ltd.. Han Lin, deputy director of Tianjin Binhai High-tech Zone Management Committee, attended the meeting. Zhang Mingrui, President of Tianjin Pharmaceutical Holdings Co., Ltd., Zhao Wei, Vice President, Xu Xiaoyang, Chief Strategy Officer, and heads of relevant departments and enterprises of Tianjin Pharmaceutical Group attended the meeting. The parties had in-depth exchanges on further opening up new areas of cooperation.

Gulas Giraud said that Mayoly Group, founded in 1909, a leading French cosmetics company in gastroenterology and dermatology, has three professional laboratories and hundreds of medicines and health care products. Tianjin Pharmaceutical Holdings Co., Ltd. is the sole partner of Mayoly Group's only pharmaceutical production base in China, the two companies have many similarities in product layout and corporate culture. Mayoly Group values the pharmaceutical and medical industry market in China very much, and is willing to further deepen the cooperation and exchanges with Tianjin High-tech Zone and Tianjin Pharmaceutical Holdings Co., Ltd., so as to create more precious opportunities and broader new market space for the growth of the enterprise.

Han Lin welcomed Nicolas Giraud's arrival. He said that Tianjin Binhai High-tech Zone is the most dynamic region in innovation and economic growth in Tianjin, which has a good foundation for the development of pharmaceutical industry and a high-quality business environment. It will spare no effort to help enterprises to solve problems and demands in operation and development, and expand their business market in China. It is hoped that through this exchange, enterprises will deepen their understanding of the medical market in China, at the same time, strengthen their confidence in the development of high-tech zones and introduce more flagship products in the future.

On behalf of Tianjin Pharmaceutical Holdings Co., Ltd., Zhang Mingrui extended a warm welcome to Nicolas Giraud and his fellows. She said that Tianjin Pharmaceutical Holdings Co., Ltd. is a large-scale pharmaceutical enterprise group with a relatively complete pharmaceutical industry chain in China. The company has been selected as one of the Top 100 Pharmaceutical Industries in China for many years, and achieved rapid growth in main business indicators in recent years. Over the years, Tianjin Pharmaceutical Holdings Co., Ltd. has maintained a good cooperative relationship with Ipsen. After taking over the cooperation with China from Ipsen, Mayoly Group hopes that the two sides will further deepen the normalized communication mechanism, and continue to conduct in-depth discussions on equity cooperation, customized product research and development, and diversified health services. In the future, the two sides will, on the basis of fast, accurate and stable cooperation, continue to promote innovation and upgrading, achieve mutual benefit, win-win cooperation and achieve the development goals of both sides.

At the meeting, it was pointed out that Tianjin Pharmaceutical Holdings Co., Ltd. and Mayoly Group had a good foundation for cooperation in brand history and product resources, and hoped to deepen their exchanges in drugs, medical devices and health products in the future, expand equity cooperation and achieve mutual benefit and win-win relation.